Bioqual (OTCMKTS:BIOQ) & Amedisys (NASDAQ:AMED) Head to Head Analysis

Bioqual (OTCMKTS:BIOQ) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Institutional & Insider Ownership

94.4% of Amedisys shares are owned by institutional investors. 39.2% of Bioqual shares are owned by company insiders. Comparatively, 2.1% of Amedisys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Bioqual and Amedisys, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioqual	0	0	0	0	0.00
Amedisys	0	1	1	0	2.50

Amedisys has a consensus target price of $100.50, indicating a potential downside of 0.50%. Given Amedisys’ stronger consensus rating and higher possible upside, analysts plainly believe Amedisys is more favorable than Bioqual.

Profitability

This table compares Bioqual and Amedisys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioqual	-4.34%	-5.82%	-3.79%
Amedisys	3.56%	12.91%	7.29%

Risk & Volatility

Bioqual has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Valuation and Earnings

This table compares Bioqual and Amedisys”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioqual	$58.59 million	0.66	$480,000.00	($2.39)	-18.07
Amedisys	$2.40 billion	1.38	$43.23 million	$2.57	39.30

Amedisys has higher revenue and earnings than Bioqual. Bioqual is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Summary

Amedisys beats Bioqual on 13 of the 14 factors compared between the two stocks.

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

About Amedisys

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer’s. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.